You searched for "regeneration"

2373 results found

Insights on medical AI for ophthalmology: an update on current perspectives

Artificial intelligence (AI) has immense promise for revolutionising medical practice. Generative AI is a form of AI in which algorithms are trained on datasets that can be used to generate new content, such as text, images or video based on...

VEGF and axial length (RVU)

The authors of this paper set out to examine whether the concentrations of VEGF in the vitreous were associated with refractive error and axial length in eyes without retinal disease, except of macular holes or epiretinal membranes. A vitreous sample...

The David J Apple International Laboratory for Ocular Pathology – a legacy of pioneering IOL research

David Apple and Gerd Auffarth. The Apple Lab at the David J Apple Center for Vision Research in Heidelberg is a thriving international laboratory for research into intraocular devices. The lab continues the work of David J Apple, a world-renowned...

Feb/Mar 2015 Quiz 1

A 79-year-old male presented to the ophthalmic emergency department with a three week history of left eye pain. He also reported visual deterioration in the left eye over the same period. He suffered from degenerative myopia, with his spectacle prescription...

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

Developments in Ophthalmology: Ophthalmic Radiation Therapy Techniques and Applications

Radiation was discovered by Wilhelm Roentgen in 1895, and since then has been used to treat a variety of cancers. Its therapeutic properties have been widely used for ocular and periocular tumours and inflammatory disease, but the present era is...

Outcomes of ‘treat and extend’ for neovascular AMD

The authors report on 24-month outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy using a ‘treat and extend’ regime for treatment-naïve neovascular age-related macular degeneration (nAMD). Data for this study was collected from the Fight Retinal Blindness observational registry based...

Aqueous humour cytokine levels in PCV and nAMD

This study looks into the possible roles of various cytokines or growth factors in the pathogenesis of exudative age-related macular degeneration (AMD) by comparing aqueous levels of 14 cytokines between eyes with polypoidal choroidal vasculopathy (PCV) and those with neovascular...

Cataract surgery in patients being treated for neovascular AMD

This retrospective matched case control study evaluated outcomes and predictive factors of visual acuity (VA) change after cataract surgery in patients being treated for neovascular age related macular degeneration (nAMD). They compared 124 patients that had cataract surgery with 372...

Exposure to atomic bomb radiation and age-related macular degeneration in later life

This paper is one of the outcomes of the Adult Health Study; a cohort study of the atomic bomb survivors of Hiroshima-Nagasaki in Japan. It investigates the proposed association between pasty radiation exposure early in life and the presence of...

Combined anti-VEGF and PDT for wet AMD

The authors report on a retrospective case series of combined anti-VEGF and photodynamic therapy (PDT) in the treatment of wet age-related macular degeneration (AMD) refractory to anti-VEGF monotherapy alone. The criteria for treatment failure of anti-VEGF monotherapy were persistent subretinal...

Four year outcomes of macular degeneration treated with ranibizumab

The authors report on a retrospective study of neovascular age-related macular degeneration (AMD) patients treated with a variable ranibizumab dosing regimen over a period of four years (from January 2007 to December 2011). A total of 600 treatment naïve eyes...